French researchers call to arms to prevent science reform


Paris – French researchers have begun massive protests to prevent the reform of the national French research system. Valérie Pecresse, the Minister of Research, had announced plans to restructure it.
According to the government’s plans, the country’s largest national research organization, the CNRS (Centre National de Recherche Scientifique), which employs more than 11,000 scientists, is to be split up into six institutes (mathematics, physics, chemistry, engineering, human sciences, ecology and biodiversity). All other research topics that have been covered by the CNRS up to now are to be dropped. Natural sciences such as biotechnology or pharmacy are to be attached to associations such as INSERM (Institut National de la Santé et de la Recherche Médicale). Because INSERM is traditionally linked to applied research, however, the scientists fear that basic research will lose ground in France. The directors of the newly established six research bodies are not to be elected by colleagues, but instead nominated by the government. Anxiety in the research community is high that the government or private sector could begin acting as sponsors for specific research. Under the new plan, public funding is only to be given to finance special, short-term projects.

Researchers fear loss of basic


The CNRS is a focus of national pride in France. It employs more than 32,000 people, including around 11,600 researchers and 14,400 engineers, technicians and administrative personnel. Its budget was EUR3.3 billion in 2008, around EUR588 million of which came from its own resources, mainly from licensing. However, according to a ranking by the Chinese Jiao Tong University (Shanghai) the structure of the CNRS is not compatible with international standards. Valérie Pecresse is trying to change that, and has reminded the protestors of two succesful predecessors. In the mid-80s, the CNRS transfer of the areas of nuclear physics and space into separate institutes was a resounding success, and went off without a hitch.



Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...



Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...



Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...



Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...



Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and...



Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...



Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance


Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance


Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Stock list

All quotes


  • DIAMYD MEDICAL -B- (S)5.70 SEK21.54%
  • QIAGEN NV (D)23.48 EUR12.29%
  • MOBERG PHARMA (S)44.10 SEK10.25%


  • MOLOGEN (D)1.81 EUR-11.71%
  • NICOX (F)9.62 EUR-8.29%
  • SAREUM HOLDINGS (UK)0.72 GBP-6.49%


  • PROTHENA PLC (IE)55.05 USD57.5%
  • DIAMYD MEDICAL -B- (S)5.70 SEK37.3%
  • VERNALIS (UK)44.50 GBP31.9%


  • MOLOGEN (D)1.81 EUR-38.4%
  • SANTHERA (CH)56.20 CHF-26.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%


  • KARO BIO (S)33.00 SEK1962.5%
  • NICOX (F)9.62 EUR425.7%
  • SAREUM HOLDINGS (UK)0.72 GBP213.0%


  • BB BIOTECH (D)44.83 EUR-84.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 29.07.2016


All Events